Meeting
2011 ASCO Annual Meeting
Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.
Authors
S. P. Anthony
Evergreen Hematology and Oncology, Spokane, WA
S. P. Anthony , I. Puzanov , P. S. Lin , K. B. Nolop , B. West , D. D. Von Hoff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
New Targets, New Technologies
Clinical Trial Registration Number
NCT01004861
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3093)
Abstract #
3093
Poster Bd #
18B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma.
First Author: Nicholas A. Butowski
Poster
2022 ASCO Annual Meeting
Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.
First Author: Sarah Shin
Poster
2021 ASCO Annual Meeting
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
First Author: Angela Tatiana Alistar
Poster
2019 ASCO Annual Meeting
A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.
First Author: Emiliano Calvo